MorphoSys is dedicated to become a fully integrated biopharmaceutical company. Our business strategy brings more value for patients, investors and partners.

First MorphoSys-antibody approved
Tremfya® (Guselkumab) now available in US, Europe and Canada!

We develop exceptional, innovative biopharmaceuticals
to improve the lives of patients suffering
from serious diseases.

Find out more about our therapeutic pipeline.

More Info

MorphoSys's vision

MorphoSys's mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Our focus is on cancer. Innovative technologies and smart development strategies are central to our approach.

learn more about the company

19/10/2018
MorphoSys's Licensee Janssen has Reported That New Tremfya(R) (...
25/09/2018
MorphoSys Announces its Licensee Janssen has Initiated a Phase 3 Trial (...
17/09/2018
MorphoSys and LEO Pharma Expand Strategic Alliance to Develop Peptide-...
13/09/2018
MorphoSys and Galapagos Announce Start of a Phase 1 Subcutaneous Bridging...
13/09/2018
MorphoSys Announces That its Licensee Janssen has Reported That Tremfya(R...
12/09/2018
MorphoSys and Galapagos Announce U.S. Antitrust Clearance for Global...
06/09/2018
MorphoSys AG to be listed in MDAX
08/08/2018
MorphoSys and I-Mab Biopharma Announce China IND Submission of TJ202/MOR202
01/08/2018
MorphoSys AG Reports Second Quarter 2018 Financial Results
24/07/2018
MorphoSys Announces Appointment of Jennifer Herron as President of...

October 16, 2018
Bloomberg Annual Healthcare Investor Conference
London, UK

See conference

 

 

 

 

Simon Moroney, CEO
on Strategy and Goals